ArticleFrontiers in oncology2025
Case Report: Surgical androgen deprivation therapy for prostate cancer in a patient with concurrent scrotal paget's disease.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prostate cancer (PCa) and Scrotal Paget's disease (SPD) are two distinct malignancies, and reports of their concurrent occurrence are very limited. The aim of this case was to discuss the individualized treatment strategy for an elderly patient with metastatic PCa combined with SPD. Case presentation: An octogenarian male (aged 88 years) with metastatic PCa (Gleason 8 = 4 + 4, bone metastases, suspected lung involvement) received androgen deprivation therapy (ADT: bicalutamide + goserelin), achieving biochemical control (PSA <0.1 ng/mL; testosterone <20 ng/dL) over three years (2020-2023). In September 2023, he developed a painless scrotal nodule (0.5 cm), which progressed to a 3 cm ulcerated lesion with pruritus and bleeding by December 2023. Histopathology confirmed SPD. After multidisciplinary review and family prioritization of symptom relief, wide local excision (3-cm margins) and bilateral orchiectomy were performed on December 9, 2023. Postoperative pathology confirmed a primary SPD (CK7+/GCDFP-15+). Postoperative recovery was uncomplicated, and no recurrence was observed at the one-year follow-up in December 2024. Clinical discussion: Dual pathology requires a multimodal approach. Surgery can control symptoms, simplify ADT, and reduce the risk of SPD recurrence. This decision requires balancing tumor efficacy, age, and quality of life (QoL). Conclusion: Combined surgical resection and ADT may benefit older patients with synchronous PCa and SPD(CK7+/GCDFP-15+), but patient selection and informed consent remain critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.